Genmab — Maj 2014
-
så er Jan blevet fanget på MedWatch: ”Det her er en meget stor skuffelse i min karriere” ... Det er sket før, og det vil ske igen. Selv rigtig gode lægemidler fejler af og til i fase 3-studier. De skuffende data for lægemidlet Arzerra var dog langt fra forventet, men Jan van de Winkel, adm. direktør i Genmab, ser fremad... læs resten på Medwatch -:)
-
Novod skriver: While FL has no clear link to DLBCL, we choose to adopt a cautious approach in the NL indications and also remove FL from our model and milestones attached to the succesful completion of phase III trials against bendamustine and Rituxan in 2016.
-
Så kom bowers også.
-
Sønker til 310
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind